A Phase 2, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MLN0002 Following Multiple Intravenous Doses in Patients With Ulcerative Colitis.
Phase of Trial: Phase II
Latest Information Update: 12 May 2016
At a glance
- Drugs Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Millennium
- 12 May 2016 Results of long-term integrated safety analysis from two phase II and four phase III trials published in a Takeda media release.
- 18 Feb 2016 Results of two phase II and four phase III studies published in the Gut.
- 01 Aug 2012 Results published in the Inflammatory Bowel Diseases.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History